
June 26 (Reuters) - Merck & Co Inc MRK.N:
ACIP RECOMMENDS USE OF MERCK’S ENFLONSIA™ (CLESROVIMAB-CFOR) FOR PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT DISEASE IN INFANTS YOUNGER THAN 8 MONTHS OF AGE BORN DURING OR ENTERING THEIR FIRST RSV SEASON
MERCK & CO INC - ENFLONSIA ORDERING BEGINS IN JULY, SHIPMENTS BEFORE 2025-2026 RSV SEASON